Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Panitumumab · Vectibix

Monoclonal antibody · Antagonist of epidermal growth factor receptor (EGFR) · developed by Amgen

Approved FDA, Sep 2006
AMGN Developer
1 Registered trials

What is Panitumumab?

Panitumumab is a fully human antibody that binds the epidermal growth factor receptor (EGFR) on normal and tumor cells and competitively blocks ligand binding, preventing receptor autophosphorylation and downstream signaling. It is studied in advanced solid tumors, and its labeled use is in metastatic colorectal cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Vectibix
Drug type
Monoclonal antibody
Targets
epidermal growth factor receptor (EGFR), KRAS (biomarker)
Mechanism
Antagonist of epidermal growth factor receptor (EGFR)
Pathways
EGFR signaling, RAS signaling, apoptosis, angiogenesis
Therapy area
Oncology
Developer
Amgen (AMGN)
FDA status
Approved as Vectibix (September 27, 2006), BLA125147 · FDA label
UNII
6A901E312A

✅ FDA-approved uses

From the indications section of the FDA label (version of Jun 23, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07172919 Phase 2 Advanced Solid Tumors Recruiting AMGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumors

Other drugs acting on EGFR

More from Amgen

Sources

Updated Nov 22, 2026. Something wrong or missing? Report it on the AMGN page.

Follow AMGN, the company behind Panitumumab

See AMGN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

AMGN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.